M Ventures – Weekly Recap

M Ventures is featured this week for advancing several key programs across its oncology and life sciences tools portfolio, reflecting steady execution on its investment strategy. The firm highlighted important clinical milestones at portfolio company Theolytics and fresh funding and pipeline progress at Lightcast and STORM Therapeutics.

Theolytics reported dosing the first patient in its U.S. Phase 1 OCTOPOD-IP trial of oncolytic immunotherapy candidate THEO-260 for platinum-resistant ovarian cancer. This intraperitoneal study is the second clinical trial for THEO-260, complementing an ongoing OCTOPOD-IV trial across the U.K., Spain, and Canada.

THEO-260 is described as a next-generation oncolytic platform targeting stroma-rich solid tumors by acting on both cancer cells and cancer-associated fibroblasts. The U.S. trial is being conducted in collaboration with MD Anderson Cancer Center under Principal Investigator Dr. Amir Jazaeri, adding external scientific and clinical validation.

In tools and platforms, Lightcast secured $27 million in new financing led by ARCH Venture Partners with participation from M Ventures and others. The capital is earmarked for a full commercial launch of its Envisia single-cell analysis benchtop system in 2026 and for scaling functional assays, manufacturing, and software capabilities.

Lightcast also appointed industry veteran Brad Crutchfield, formerly chief commercial officer at 10x Genomics, as an advisor to its board. His experience is expected to support refinement of the company’s commercial strategy in antibody discovery, oncology therapeutics, and cell line development, potentially enhancing its market positioning.

On the oncology therapeutics side, STORM Therapeutics completed a $56 million Series C round to advance its RNA-modification targeting pipeline. Proceeds will help accelerate clinical development of STC-15, a first-in-class oral METTL3 inhibitor, as it progresses through ongoing studies.

STORM has already dosed the first patient in a Phase 2 monotherapy trial of STC-15 in selected sarcoma indications, marking a significant clinical step for the asset. These financing and development updates may improve visibility on STORM’s path in precision oncology and support future strategic options.

Taken together, the week’s developments underscore continued momentum for M Ventures’ portfolio in both high-need oncology segments and advanced research platforms. The combination of new capital, clinical progression, and strengthened partnerships points to a constructive near-term outlook for the firm’s value creation efforts.